Table 2.
Summary data from the human ovarian tumours Cohort 2
| Histology | N | Mean age (range) | Median Grade | Median Stage | Surgery (Number of patients) |
Platinum Status (Number of patients) |
Median PFS | Median OS | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Interval | Sensitive | Resistant | |||||||
| Pelvic serous carcinoma | 44 | 60.18 (25–81) | 3 | 3 | 30 | 14 | 33 | 5 | 13.5 | 41 |
| Endometrioid adenocarcinoma | 12 | 63 (44–84) | 2 | 1 | 12 | 0 | 10 | 0 | 97 | 105 |
| Mucinous adenocarcinoma | 6 | 64.67 (42–84) | 3 | 3 | 6 | 0 | 1 | 2 | 1 | 9.5 |
| Clear cell carcinoma | 1 | 58 | 3 | 3 | 1 | 0 | – | – | 1 | 1 |
| MMMT | 3 | 71.67 (69–75) | 3 | 3 | 2 | 1 | – | 2 | 1.5 | 5 |
| Borderline epithelial tumour | 17 | 54.18 (25–89) | – | – | 17 | 0 | – | – | – | – |
| Benign tumour | 7 | 64.86 (46–80) | – | – | 7 | 0 | – | – | – | – |